Comparison of Insulin Detemir With Insulin Glargine in Type 2 Diabetes

Phase 3

Completed

• Conditions: Diabetes Mellitus, Type 2; Diabetes

• Registration Number: NCT00106366
• Lead Sponsor: Novo Nordisk A/S

Brief Summary

This trial is conducted in the United States of America (USA). The purpose of this study is to determine if the use of insulin detemir in combination with insulin aspart is safe and at least as effective as insulin glargine in combination with insulin aspart for the control of blood glucose in patients with Type 2 diabetes.

Detailed Description

Not available

Study Timeline

• Study Start: 2005-03
• Study First Submitted: 2005-03-22
• Study First Submitted QC: 2005-03-22
• Study First Posted: 2005-03-23
• Primary Completion: 2005-12
• Study Completion: 2005-12
• Status Verified: 2017-01
• Last Update Submitted: 2017-01-30
• Last Update Posted: 2017-01-31

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 389

Inclusion Criteria

• Type 2 Diabetes for more than 12 months
• Currently treated with glucose lowering tablets or insulin
• HbA1c: 7.0-12.0%

Exclusion Criteria

Not provided

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Primary Outcome Measures

Name	Time	Method
HbA1c	after 26 weeks

Secondary Outcome Measures

Name	Time	Method
Body weight
Glucose profiles

Trial Locations

Locations (1)

Novo Nordisk Investigational Site; 🇵🇷 Rio Piedras, Puerto Rico